Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    Open Studies | "hospital of central connecticut"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "hospital of central connecticut" (52 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
2 Recruiting Cardiovascular Inflammation Reduction Trial
Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate;   Drug: Placebo
3 Recruiting Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Condition: Chronic Lymphocytic Leukemia
Intervention:
4 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
5 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
7 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
8 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
9 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
Interventions: Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: methotrexate;   Procedure: quality-of-life assessment
10 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm to the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy;   Other: Laboratory Biomarker Analysis
11 Recruiting Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: AEZS-108 / zoptarelin doxorubicin;   Drug: doxorubicin
12 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
13 Recruiting COOL-ARREST Pilot Study to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest
Condition: Out of Hospital Cardiac Arrest
Intervention: Device: ZOLL Intravascular Temperature Management System (IVTM)
14 Recruiting Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva
Conditions: Squamous Cell Carcinoma of the Vulva;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Vulvar Cancer
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Procedure: therapeutic conventional surgery
15 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
16 Recruiting Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Atypical Glandular Cell of Undetermined Significance;   Cervical Cancer;   Cervical Intraepithelial Neoplasia Grade 2;   Cervical Intraepithelial Neoplasia Grade 3;   Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
17 Recruiting Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observation
18 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
19 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Radiation: brachytherapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin
20 Recruiting Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel;   Drug: Trastuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years